Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences By: Evolus via Business Wire February 27, 2024 at 08:30 AM EST Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conferences in March. Event: The Leerink Partners Global Biopharma Conference 2024 Date: Tuesday, March 12th, 2024 Time: 10:00-10:30am ET Event: The Barclays 26th Annual Global Healthcare Conference Date: Wednesday, March 13th, 2024 Time: 8:00-8:25am ET The fireside chats can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of the presentation. About Evolus, Inc. Evolus (Nasdaq: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook. Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc. Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd. View source version on businesswire.com: https://www.businesswire.com/news/home/20240227499486/en/ Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences Contacts Investors: Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications Phone: (248) 202-9267 Email: ir@evolus.com Media: Email: media@evolus.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences By: Evolus via Business Wire February 27, 2024 at 08:30 AM EST Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conferences in March. Event: The Leerink Partners Global Biopharma Conference 2024 Date: Tuesday, March 12th, 2024 Time: 10:00-10:30am ET Event: The Barclays 26th Annual Global Healthcare Conference Date: Wednesday, March 13th, 2024 Time: 8:00-8:25am ET The fireside chats can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of the presentation. About Evolus, Inc. Evolus (Nasdaq: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook. Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc. Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd. View source version on businesswire.com: https://www.businesswire.com/news/home/20240227499486/en/ Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences Contacts Investors: Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications Phone: (248) 202-9267 Email: ir@evolus.com Media: Email: media@evolus.com
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conferences in March. Event: The Leerink Partners Global Biopharma Conference 2024 Date: Tuesday, March 12th, 2024 Time: 10:00-10:30am ET Event: The Barclays 26th Annual Global Healthcare Conference Date: Wednesday, March 13th, 2024 Time: 8:00-8:25am ET The fireside chats can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of the presentation. About Evolus, Inc. Evolus (Nasdaq: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook. Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc. Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd. View source version on businesswire.com: https://www.businesswire.com/news/home/20240227499486/en/
Investors: Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications Phone: (248) 202-9267 Email: ir@evolus.com Media: Email: media@evolus.com